Login to Your Account

NPS Eyes NDA Filing For Preos On Positive Osteoporosis Trials

By Randall Osborne

Wednesday, March 31, 2004
Neither a fizzled merger nor worries over clinical trial supply of its osteoporosis drug Preos kept NPS Pharmaceuticals Inc. from forging ahead with the pivotal Phase III study and meeting the primary endpoint of reducing vertebral fractures in the top-line data analysis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription